AR116472A1 - Sal de ácido quiral de (-)-cibenzolina, proceso para la preparación de su sal enantioméricamente pura y composición farmacéutica que la comprende; forma cristalina de la misma, un método para su obtención y una composición farmacéutica que comprende a dicha forma cristalina - Google Patents

Sal de ácido quiral de (-)-cibenzolina, proceso para la preparación de su sal enantioméricamente pura y composición farmacéutica que la comprende; forma cristalina de la misma, un método para su obtención y una composición farmacéutica que comprende a dicha forma cristalina

Info

Publication number
AR116472A1
AR116472A1 ARP190102683A ARP190102683A AR116472A1 AR 116472 A1 AR116472 A1 AR 116472A1 AR P190102683 A ARP190102683 A AR P190102683A AR P190102683 A ARP190102683 A AR P190102683A AR 116472 A1 AR116472 A1 AR 116472A1
Authority
AR
Argentina
Prior art keywords
acid
tartaric
crystalline form
pharmaceutical composition
dibenzoyl
Prior art date
Application number
ARP190102683A
Other languages
English (en)
Inventor
Vikas Shivaji Patil
Dnyandev Ragho Rane
Vijayavitthal Thippannachar Mathad
Reddy Srinivas Reddy Desi
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of AR116472A1 publication Critical patent/AR116472A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal de ácido quiral de (-)-Cibenzolina, una composición farmacéutica que la comprende y un método para la preparación de la misma de forma enantioméricamente pura. Se provee además una forma cristalina de succinato de (-)-Cibenzolina, un proceso para su obtención y una composición farmacéutica que la comprende. Reivindicación 1: Sal de ácido quiral de (-)-Cibenzolina de fórmula (1), en donde el ácido quiral es uno seleccionado del grupo que consiste en ácido L-(+)-tartárico, ácido D-(-)-tartárico, ácido (R)-(-)-mandélico, ácido (S)-(+)-mandélico, ácido dibenzoil-L-tartárico, ácido (+)-2,3-dibenzoil-D-tartárico, ácido (-)-O,O’-dibenzoil-L-tartárico monohidrato, ácido (+)-O,O-dibenzoil-D-tartárico monohidrato, mono(dimetilamida) del ácido (-)-O,O’-dibenzoil-L-tartárico, ácido di-p-toluoil-D-tartárico monohidrato, ácido di-p-toluoil-L-tartárico monohidrato, ácido (-)-O,O’-di-p-toluoil-L-tartárico, ácido (+)-O,O’-di-p-toluoil-D-tartárico, ácido D-glutámico, ácido L-glutámico, ácido L-(-)-málico, ácido D-(+)-málico, ácido (-)-mentiloxiacético, ácido (+)-mentiloxiacético, ácido (R)-(+)-a-metoxi-a-trifluorometilfenilacético, ácido (S)-(-)-a-metoxi-a-trifluorometilfenilacético, ácido (R)-(-)-5-oxo-2-tetrahidrofuranocarboxílico, ácido (S)-(+)-5-oxo-2-tetrahidrofuranocarboxílico, ácido (R)-(+)-N-(1-feniletil)ftalámico, ácido (S)-(-)-N-(1-feniletil)ftalámico, ácido (R)-(-)-2-fenilpropiónico, ácido (S)-(+)-2-fenilpropiónico, ácido L-piroglutámico, ácido D-piroglutámico, ácido D-(-)-quínico, ácido L-(+)-quínico, ácido L-aspártico, ácido D-aspártico, ácido (R)-1-4-benzodioxano-2-carboxílico, ácido (S)-1,4-benzodioxano-2-carboxílico, ácido N,N-bis[(S)-(-)-1-feniletil]ftalámico, ácido N,N-bis[(R)-(+)-1-feniletil]ftalámico, bromocanfor-10-sulfónico hidrato, ácido (1S)-(-)-canfánico, ácido (1R)-(+)-canfánico, ácido (1R,3S)-(+)-canfórico, ácido (1S,3R)-(-)-canfórico, ácido (1R)-(-)-10-canforsulfónico y ácido (1S)-(+)-10-canforsulfónico. Reivindicación 7: Una forma cristalina de succinato de (-)-Cibenzolina de fórmula (2). Reivindicación 8: La forma cristalina de succinato de (-)-Cibenzolina de acuerdo con la reivindicación 7, en donde la forma cristalina tiene un patrón de difracción de rayos X de polvo (XRPD) que incluye picos de difracción a 11,2º, 14,1º, 17,3º, 22,1º, 23,0º y 24,3º (2q ± 0,2º).
ARP190102683A 2018-09-28 2019-09-20 Sal de ácido quiral de (-)-cibenzolina, proceso para la preparación de su sal enantioméricamente pura y composición farmacéutica que la comprende; forma cristalina de la misma, un método para su obtención y una composición farmacéutica que comprende a dicha forma cristalina AR116472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201841036791 2018-09-28

Publications (1)

Publication Number Publication Date
AR116472A1 true AR116472A1 (es) 2021-05-12

Family

ID=69953156

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102683A AR116472A1 (es) 2018-09-28 2019-09-20 Sal de ácido quiral de (-)-cibenzolina, proceso para la preparación de su sal enantioméricamente pura y composición farmacéutica que la comprende; forma cristalina de la misma, un método para su obtención y una composición farmacéutica que comprende a dicha forma cristalina

Country Status (10)

Country Link
US (1) US20230122169A1 (es)
EP (1) EP3858816A4 (es)
JP (1) JP7414814B2 (es)
KR (1) KR20200036755A (es)
CN (1) CN112739686A (es)
AR (1) AR116472A1 (es)
AU (1) AU2019347545A1 (es)
CA (1) CA3109210A1 (es)
TW (1) TW202024035A (es)
WO (1) WO2020067684A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021258979B2 (en) * 2020-04-23 2024-02-29 Celltrion Inc. Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition
CN112939852B (zh) * 2021-02-03 2023-02-24 凯莱英医药化学（阜新）技术有限公司 芳香环丙烷衍生物消旋异构体的拆分方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417174A (en) * 1972-11-30 1975-12-10 Hexachimie 1-2-delta2-imidazolinyl-2,2-diarylcoclopropanes
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
JPH0770070A (ja) * 1993-09-03 1995-03-14 Eisai Kagaku Kk 光学活性な１−（４−クロロピリジン−２−イル）−２−（ピリジン−２−イル）エチルアミンの製造法および中間体
CN1119330C (zh) * 1994-05-16 2003-08-27 默里尔药物公司 用于光学拆分外消旋哌啶丁醇和其衍生化合物的方法和非对映体盐
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US20110118239A1 (en) 2008-01-15 2011-05-19 Targacept, Inc. Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane and novel salt forms of the racemate and enantiomers
WO2009106486A1 (en) 2008-02-26 2009-09-03 Sandoz Ag Preparation of morpholine derivatives
JP2010132561A (ja) * 2008-12-02 2010-06-17 Dnp Fine Chemicals Fukushima Co Ltd コハク酸シベンゾリンの新規ａ型結晶及びその製造方法
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
JP2012136526A (ja) 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法

Also Published As

Publication number Publication date
JP2022502445A (ja) 2022-01-11
WO2020067684A1 (ko) 2020-04-02
TW202024035A (zh) 2020-07-01
US20230122169A1 (en) 2023-04-20
KR20200036755A (ko) 2020-04-07
CA3109210A1 (en) 2020-04-02
CN112739686A (zh) 2021-04-30
JP7414814B2 (ja) 2024-01-16
EP3858816A4 (en) 2022-06-15
AU2019347545A1 (en) 2021-03-11
EP3858816A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
AR116472A1 (es) Sal de ácido quiral de (-)-cibenzolina, proceso para la preparación de su sal enantioméricamente pura y composición farmacéutica que la comprende; forma cristalina de la misma, un método para su obtención y una composición farmacéutica que comprende a dicha forma cristalina
NZ596713A (en) Sitagliptin synthesis
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
FI117436B (fi) Menetelmä levobupivakaiinin ja sen analogien optisesti rikastuneen muodon rasemisoimiseksi
NO20075625L (no) Fremgangsmate for dynamisk opplosning av (substituert) (R)- eller (S) -mandelsyre
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
AR058626A1 (es) Proceso para la preparacion de compuestos de 6,6 - dimetil -3- azabiciclo -(3.1.0)- hexano y sales enantiomericas de los mismos
WO2006065826A3 (en) Process to chiral beta amino acid derivatives by asymmetric hydrogenation
RS54529B1 (en) PHENOXIMETHYL HETEROCYCLIC COMPOUNDS
HRP20150738T1 (hr) Postupak za pripremu r-(-)-3-(karbamoilmetil)-5-metilheksanske kiseline i pregabalina i sintezu intermedijera
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
EA200702072A1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
HRP20201405T1 (hr) Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
EA201891437A1 (ru) Способ разделения энантиомеров пиперазиновых производных
ATE453622T1 (de) Verfahren zur herstellung von enantiomeren angereicherten cyclischen beta-aryl- oder heteroarylcarbonsäuren
AU2009305477B2 (en) Process for the preparation of optically active (S)-(-)-2- (N-propylamino)-5-methoxytetraline and (S)-(-)-2- (N-propylamino)-5-hydroxytetraline compounds
RU2005134685A (ru) Способ разделения аминов, которые являются полезными для лечения расстройств, ассоциированных с синдромом инсулинрезистентности
RU2019128576A (ru) Сокристаллы замещенных глициновых соединений и их применение
AR057451A1 (es) Metodos para preparar derivados de acido glutamico
RU2012102671A (ru) Новые фумаратные соли антагониста гистаминового рецептора н3
BRPI0408680A (pt) processo para produzir álcoois e aminas enantiomericamente enriquecidos
EA201291302A1 (ru) Синтез циклопентахиназолинов
GEP20156308B (en) New process for synthesis of (2e)-3-(3,4-dimethoxyphenyl) prop-2-enenitrile, and application in synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid
BR0215593A (pt) Processo para produzir ácido (r)-3-hidróxi-3-(2-feniletil)-hexanóico e seu intermediário
DE602007010926D1 (de) Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure